WATERTOWN, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (www.dicerna.com), a second generation RNA interference company developing novel therapeutics utilizing proprietary Dicer Substrate Technology™, announced today the appointment of leading experts to its Scientific Advisory Board (SAB). The newly appointed SAB will serve as a strategic asset to the company as it continues to develop novel RNAi-based therapies that use an earlier step in the gene silencing process, namely the engagement of the enzyme Dicer, which is a natural initiation point for the RNAi cascade.
